Tech Company Financing Transactions
Cellumen Funding Round
Cellumen secured a $10.7 million Series B investment round on 7/10/2007. Investors included Novitas Capital and Safeguard Scientifics.
Transaction Overview
Company Name
Announced On
7/10/2007
Transaction Type
Venture Equity
Amount
$10,700,000
Round
Series B
Investors
Safeguard Scientifics (Michael Pellini)
Proceeds Purpose
Cellumen intends to use the proceeds from this financing to complete its management team, further develop its product catalog, continue its CSB platform development, and commercialize its cellular models of disease and cytotoxicity profiling services and products.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3180 William Pitt Way
Pittsburgh, PA 15238
USA
Pittsburgh, PA 15238
USA
Phone
Website
Email Address
Overview
Cellumen is a systems cell biology company that is focused on defining the functions of genes, coding and non-coding RNA's, proteins and other cellular constituents that regulate and perform the myriad of functions that define normal life and are related to specific disease processes as potential biomarkers and/or targets for drug discovery and patient profiling.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lansing Taylor
Chief Financial Officer
Gregory Finerty
Chief Scientific Officer
Kenneth Giuliano
Vice President
Albert Gough
Vice President
Patricia Johnston
VP - Bus. Development
Donald Taylor
Browse more venture capital transactions:
Prev: 7/10/2007: National Banana venture capital transaction
Next: 7/10/2007: Light Sciences Oncology venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs